Qing Cheng1, William Butler2, Yinglu Zhou2, Hong Zhang2, Lu Tang2, Kathryn Perkinson2, Xufeng Chen2, Xiaoyin Sara Jiang3, Shannon J McCall3, Brant A Inman4, Jiaoti Huang5. 1. Department of Surgery, Duke University School of Medicine, Durham, NC, USA; Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA. Electronic address: Q.Cheng@duke.edu. 2. Department of Pathology, Duke University School of Medicine, Durham, NC, USA. 3. Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA; Department of Pathology, Duke University School of Medicine, Durham, NC, USA. 4. Department of Surgery, Duke University School of Medicine, Durham, NC, USA; Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA. Electronic address: brant.inman@duke.edu. 5. Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA; Department of Pathology, Duke University School of Medicine, Durham, NC, USA. Electronic address: Jiaoti.Huang@duke.edu.
Abstract
BACKGROUND: Hormonal therapy targeting the androgen receptor inhibits prostate cancer (PCa), but the tumor eventually recurs as castration-resistant prostate cancer (CRPC). OBJECTIVE: To understand the mechanisms by which subclones within early PCa develop into CRPC. DESIGN, SETTING, AND PARTICIPANTS: We isolated epithelial cells from fresh human PCa cases, including primary adenocarcinoma, locally recurrent CRPC, and metastatic CRPC, and utilized single-cell RNA sequencing to identify subpopulations destined to become either CRPC-adeno or small cell neuroendocrine carcinoma (SCNC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We revealed dynamic transcriptional reprogramming that promotes disease progression among 23226 epithelial cells using single-cell RNA sequencing, and validated subset-specific progression using immunohistochemistry and large cohorts of publically available genomic data. RESULTS AND LIMITATIONS: We identified a small fraction of highly plastic CRPC-like cells in hormone-naïve early PCa and demonstrated its correlation with biochemical recurrence and distant metastasis, independent of clinical characteristics. We show that progression toward castration resistance was initiated from subtype-specific lineage plasticity and clonal expansion of pre-existing neuroendocrine and CRPC-like cells in early PCa. CONCLUSIONS: CRPC-like cells are present early in the development of PCa and are not exclusively the result of acquired evolutionary selection during androgen deprivation therapy. The lethal CRPC and SCNC phenotypes should be targeted earlier in the disease course of patients with PCa. PATIENT SUMMARY: Here, we report the presence of pre-existing castration-resistant prostate cancer (CRPC)-like cells in primary prostate cancer, which represents a novel castration-resistant mechanism different from the adaptation mechanism after androgen deprivation therapy (ADT). Patients whose tumors harbor increased pre-existing neuroendocrine and CRPC-like cells may become rapidly resistant to ADT and may require aggressive early intervention.
BACKGROUND: Hormonal therapy targeting the androgen receptor inhibits prostate cancer (PCa), but the tumor eventually recurs as castration-resistant prostate cancer (CRPC). OBJECTIVE: To understand the mechanisms by which subclones within early PCa develop into CRPC. DESIGN, SETTING, AND PARTICIPANTS: We isolated epithelial cells from fresh human PCa cases, including primary adenocarcinoma, locally recurrent CRPC, and metastatic CRPC, and utilized single-cell RNA sequencing to identify subpopulations destined to become either CRPC-adeno or small cell neuroendocrine carcinoma (SCNC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We revealed dynamic transcriptional reprogramming that promotes disease progression among 23226 epithelial cells using single-cell RNA sequencing, and validated subset-specific progression using immunohistochemistry and large cohorts of publically available genomic data. RESULTS AND LIMITATIONS: We identified a small fraction of highly plastic CRPC-like cells in hormone-naïve early PCa and demonstrated its correlation with biochemical recurrence and distant metastasis, independent of clinical characteristics. We show that progression toward castration resistance was initiated from subtype-specific lineage plasticity and clonal expansion of pre-existing neuroendocrine and CRPC-like cells in early PCa. CONCLUSIONS: CRPC-like cells are present early in the development of PCa and are not exclusively the result of acquired evolutionary selection during androgen deprivation therapy. The lethal CRPC and SCNC phenotypes should be targeted earlier in the disease course of patients with PCa. PATIENT SUMMARY: Here, we report the presence of pre-existing castration-resistant prostate cancer (CRPC)-like cells in primary prostate cancer, which represents a novel castration-resistant mechanism different from the adaptation mechanism after androgen deprivation therapy (ADT). Patients whose tumors harbor increased pre-existing neuroendocrine and CRPC-like cells may become rapidly resistant to ADT and may require aggressive early intervention.
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Ping Mu; Zeda Zhang; Matteo Benelli; Wouter R Karthaus; Elizabeth Hoover; Chi-Chao Chen; John Wongvipat; Sheng-Yu Ku; Dong Gao; Zhen Cao; Neel Shah; Elizabeth J Adams; Wassim Abida; Philip A Watson; Davide Prandi; Chun-Hao Huang; Elisa de Stanchina; Scott W Lowe; Leigh Ellis; Himisha Beltran; Mark A Rubin; David W Goodrich; Francesca Demichelis; Charles L Sawyers Journal: Science Date: 2017-01-06 Impact factor: 47.728
Authors: Yan Ping Yu; Douglas Landsittel; Ling Jing; Joel Nelson; Baoguo Ren; Lijun Liu; Courtney McDonald; Ryan Thomas; Rajiv Dhir; Sydney Finkelstein; George Michalopoulos; Michael Becich; Jian-Hua Luo Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler Journal: Science Date: 2013-03-29 Impact factor: 47.728
Authors: Maxim V Kuleshov; Matthew R Jones; Andrew D Rouillard; Nicolas F Fernandez; Qiaonan Duan; Zichen Wang; Simon Koplev; Sherry L Jenkins; Kathleen M Jagodnik; Alexander Lachmann; Michael G McDermott; Caroline D Monteiro; Gregory W Gundersen; Avi Ma'ayan Journal: Nucleic Acids Res Date: 2016-05-03 Impact factor: 16.971
Authors: Meng Xiao He; Michael S Cuoco; Jett Crowdis; Alice Bosma-Moody; Zhenwei Zhang; Kevin Bi; Abhay Kanodia; Mei-Ju Su; Sheng-Yu Ku; Maria Mica Garcia; Amalia R Sweet; Christopher Rodman; Laura DelloStritto; Rebecca Silver; John Steinharter; Parin Shah; Benjamin Izar; Nathan C Walk; Kelly P Burke; Ziad Bakouny; Alok K Tewari; David Liu; Sabrina Y Camp; Natalie I Vokes; Keyan Salari; Jihye Park; Sébastien Vigneau; Lawrence Fong; Joshua W Russo; Xin Yuan; Steven P Balk; Himisha Beltran; Orit Rozenblatt-Rosen; Aviv Regev; Asaf Rotem; Mary-Ellen Taplin; Eliezer M Van Allen Journal: Nat Med Date: 2021-03-04 Impact factor: 53.440
Authors: André Marquardt; Philip Kollmannsberger; Markus Krebs; Antonella Argentiero; Markus Knott; Antonio Giovanni Solimando; Alexander Georg Kerscher Journal: Genes (Basel) Date: 2022-07-26 Impact factor: 4.141
Authors: Maja Marklund; Niklas Schultz; Stefanie Friedrich; Emelie Berglund; Firas Tarish; Anna Tanoglidi; Yao Liu; Ludvig Bergenstråhle; Andrew Erickson; Thomas Helleday; Alastair D Lamb; Erik Sonnhammer; Joakim Lundeberg Journal: Nat Commun Date: 2022-09-17 Impact factor: 17.694